{"id":32386,"date":"2020-07-21T11:15:21","date_gmt":"2020-07-21T10:15:21","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=32386"},"modified":"2021-03-18T11:13:27","modified_gmt":"2021-03-18T11:13:27","slug":"biosimilars-biologics-2017-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/","title":{"rendered":"Biosimilars & Biologics 2017 Speakers"},"content":{"rendered":"
\n

\n\tOur
Speakers (A-Z)
\n\t<\/h2>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32491″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/abhishek-kulshrestha\/abhishek_kulshrestha_biocon_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Abhishek_Kulshrestha_Biocon_BioTech_Pharma_Summit_Profile_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAbhishek Kulshrestha\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Principal Scientific manager at Biocon<\/h5>\n

\n\t\t\t\n\tBiosimilarity assessment- The process of designing biosimilars\n\t\t\t<\/a>\n\t<\/h3>\n\t

Abhishek is working as Principal scientific Manager at Biocon. In Biocon, he leads the Biosimilar recombinant human Insulin program for regulated markets. He also leads the bioanalytical functions related to Pharmacokinetics, Immunogenicity and HCP assessment. With close to 10 years of industry experience in biosimilar and biologics development, he has successfully led research teams working on phage display based antibody libraries, mammalian and bacterial cell line development, bioassays and bioanalytical development.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32472″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/antonio-pregueiro\/antonio_pregueiro_biotech_pharma_summit_porto_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/antonio_pregueiro_BioTech_Pharma_Summit_Porto_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAnt\u00f3nio Pregueiro\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President Life Sciences Europe at HighPoint Solutions<\/h5>\n

\n\t\t\t\n\tBiosimilars: A market to grow\n\t\t\t<\/a>\n\t<\/h3>\n\t

Ant\u00f3nio Pregueiro, PhD has over 12 years of experience in the pharmaceutical and biotechnology industries combined with a strong research background prior to his business career. Following his graduate training, he spent 5 years working in consulting firms focused in the life-sciences developing expertise in strategy, management and technology across several therapeutic areas. He worked globally, gaining experience in the US, Europe, South America, Russia and the Middle East.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32454″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/arnout-ploos-van-amstel\/arnout_ploos_van_amstel_biotech_pharma_summit_novartis_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"4","credit":"","camera":"Canon EOS 6D","caption":"","created_timestamp":"1475829406","copyright":"","focal_length":"100","iso":"200","shutter_speed":"0.01","title":"","orientation":"1"}” data-image-title=”Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Arnout_Ploos_van_Amstel_BioTech_Pharma_Summit_Novartis_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tArnout Ploos van Amstel\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of Global Business Franchise Immunology & Dermatology (I&D) at Novartis Pharmaceuticals<\/h5>\n

\n\t\t\t\n\tSustainable biotech innovation and the emergence of biosimilars: opportunities to create enterprise synergies and enhance patient outcomes\n\t\t\t<\/a>\n\t<\/h3>\n\t

Arnout Ploos van Amstel has over 25 years of business and operations experience in the bio-pharmaceutical business in a wide variety of leadership positions. Currently, Mr Ploos van Amstel leads the Global Business Franchise Immunology & Dermatology (I&D) at Novartis Pharmaceuticals. The I&D Business of $3,2bn includes the recently launched, game changing biologic Cosentyx, the first IL17A inhibitor. Cosentyx addresses significant unmet needs for patients with the skin disease Psoriasis and the rheumatology disorders Psoriatric Arthritis (PsA) and Ankylosing Spondylitis (AS). It is one of the most promising assets of Novartis.<\/p>\n\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32407″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/cecil-nick\/cecil_nick_bio_tech_pharma_summit_porto_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1509668805","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/cecil_nick_Bio_Tech_Pharma_Summit_Porto_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tCecil Nick\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President at PAREXEL<\/h5>\n

\n\t\t\t\n\tAnalytical Comparability of Biologics and Biosimilars\n\t\t\t<\/a>\n\t<\/h3>\n\t

Cecil Nick, Vice President (Technical), at PAREXEL Consulting has been working in regulatory affairs and clinical development for over 30 years; for over 25 years he has focused on biological medicines. Cecil Nick has particular expertise in monoclonals and biosimilars, having worked on over 20 such programs, engaged in over 50 interactions and meetings with regulatory agencies in the EU, US, Canada, Australia, Mexico, Brazil and supported 6 submissions in the EU and US including the first monoclonal biosimilar to be approved in the EU and US<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32430″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/dairine-dempsey\/dairine_dempsey_headshot_open_orphan_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Dairine_Dempsey_Headshot_Open_Orphan_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Dairine_Dempsey_Headshot_Open_Orphan_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tDairine Dempsey\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO & co-founder at Open Orphan DAC<\/h5>\n

\n\t\t\t\n\tOverview of the regulatory Landscape for Biologics and Biosimilars\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Dairine Dempsey is the CEO\/CMO & a co-founder of Open Orphan DAC, a Dublin-based EU pharmaceutical company specialised in bringing orphan drugs to EU patients.<\/p>\n

Dairine has over 15 years experience in the pharmaceutical industry including almost 10 years in the national regulatory authority for medicines (now the Health products Regulatory Authority).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32392″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/edward-abrahams\/edward_abrahams_biotech_pharma_porto_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"","camera":"NIKON D2Xs","caption":"","created_timestamp":"1366217368","copyright":"","focal_length":"600","iso":"250","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Edward_Abrahams_BioTech_Pharma_Porto_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Edward_Abrahams_BioTech_Pharma_Porto_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tEdward Abrahams\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
President at Personalized Medicine Coalition (PMC)<\/h5>\n

\n\t\t\t\n\tWhy Personalized Medicine Matters?\n\t\t\t<\/a>\n\t<\/h3>\n\t

Edward Abrahams, Ph.D., is the president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32443″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/fiona-greer\/fiona_greer_biotech_pharma_porto_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Fiona_Greer_BioTech_Pharma_Porto_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Fiona_Greer_BioTech_Pharma_Porto_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tFiona Greer\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Life Sciences Global Director, Biopharma Services Development at SGS<\/h5>\n

\n\t\t\t\n\tEstablishing \u201cFinger-print Like\u201d Biosimilarity \u2013 Critical Characterization Strategies for Biosimilar Assessment\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr Fiona Greer was a founding Director of M-Scan (Mass Spectrometry Consultants and Analysts), contract analytical laboratories specializing in biopharmaceutical characterization. Following acquisition in 2010, she is now Global Director, Biopharma Services Development, SGS Life Sciences.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32466″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/javier-camposano\/javier_camposano_celltrion_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.2","credit":"","camera":"iPhone 6","caption":"","created_timestamp":"1476810771","copyright":"","focal_length":"4.15","iso":"64","shutter_speed":"0.033333333333333","title":"","orientation":"1"}” data-image-title=”Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Javier_Camposano_Celltrion_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJavier Camposano\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of the Drug Product Division at Celltrion\u2019s Inc.<\/h5>\n

\n\t\t\t\n\tBiosimilars Interchangeability and Extrapolation\n\t\t\t<\/a>\n\t<\/h3>\n\t

Javier Camposano is the Managing Director and Head of the Drug Product Division at Celltrion\u2019s Inc. South Korea. Prior to Celltrion he worked for Baxter for 17 years in a variety of technical and Management positions, including Facility and Equipment Project managing, Leading Aseptic Filling Capital Projects, participating in commercial development projects and Supervising cross functional projects between facilities.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32424″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/joanna-brougher\/joanna_brougher_biotech_pharma_summit_gallery\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1477076066","copyright":"Michal-Kathryn","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Joanna_Brougher_BioTech_Pharma_Summit_Gallery” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Joanna_Brougher_BioTech_Pharma_Summit_Gallery-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJoanna Brougher\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Owner & Principal at BioPhama Law Group, PLLC<\/h5>\n

\n\t\t\t\n\tObtaining patent protection while operating in an “anti-patent” climate\n\t\t\t<\/a>\n\t<\/h3>\n\t

Joanna is a patent attorney who focuses her practice on all aspects of services related to patents in the life sciences. Joanna has experience counseling clients on the Hatch-Waxman Act and is monitoring developments involving biosimilars under the Biologics Price Competition and Innovation Act. Joanna is also an Adjunct Lecturer at the Harvard T.H. Chan School of Public Health and the Editor-in-Chief of the Journal of Commercial Biotechnology.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32449″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/paul-song\/paul_song_samsung-bioepsis_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"9.5","credit":"","camera":"FinePixS2Pro","caption":"","created_timestamp":"1361509464","copyright":"","focal_length":"70","iso":"100","shutter_speed":"0.016666666666667","title":"","orientation":"1"}” data-image-title=”Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Paul_Song_Samsung-Bioepsis_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tPaul Song\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President at Samsung Bioepsis<\/h5>\n

\n\t\t\t\n\tBiosimilar Development at Samsung Bioepis\n\t\t\t<\/a>\n\t<\/h3>\n\tDr. Paul H. Song has 23yrs of in-depth biologics drug discovery\/development experiences in both innovative biologics and biosimilar drugs targeting immunology and oncology indications.
\nIn his current role as Vice President at Samsung Bioepsis, Paul is leading the Cell Engineering team with responsibilities for generating commercial production cell lines for the 2nd wave biosimilars targeting both oncology and immunology indications, and technology development for advanced production cell line and vector system.\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32419″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/rodeina-challand\/rodeina_challand_consulting_biotech_pharma_summit_profile_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRodeina Challand\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director at Challand Biosimilar Consulting Ltd.<\/h5>\n

\n\t\t\t\n\tBiosimilar Orphan Drugs: The Next Regulatory Challenge\n\t\t\t<\/a>\n\t<\/h3>\n\t

Rodeina Challand B.Sc., Director, Challand Biosimilar Consulting Ltd., Graduate from London University with over 25 years of experience in healthcare, cancer research and pharmaceutical industry across a wide range of roles including developing and implementing clinical development strategies for biosimilars at Hospira Inc. as Director of Clinical Projects and Head of Clinical Operations in the EU.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32478″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/samir-kulkarni\/samir_kulkarni_intas_pharma_biotech_summit_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"GT-I9300","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Samir_Kulkarni_Intas_Pharma_BioTech_Summit_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSamir Kulkarni\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Associate Vice President, Product Development and Strategic Program Management at Intas Biopharmaceuticals<\/h5>\n

\n\t\t\t\n\tProcess development in R&D for event free manufacturing\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Samir Kulkarni is leading the Process Development efforts at Intas Biopharmaceuticals as an Associate Vice President. He holds a PhD in Chemical Engineering in addition to which, his educational background includes a combination of faculties such as Pharmaceutical Sciences, BioProcessing and Business Administration from Reputed institutes such as ICT (Mumbai) and IIM (Bangalore).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32460″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/sarah-rickwood\/sarah_rickwood_quintilesims_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.8","credit":"Joshua Tucker","camera":"Canon EOS-1D X","caption":"","created_timestamp":"1474983387","copyright":"JoshuaTuckerPhotography.com","focal_length":"110","iso":"3200","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Sarah_Rickwood_quintilesIMS_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSarah Rickwood\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President, Thought Leadership at QuintilesIMS<\/h5>\n

\n\t\t\t\n\tFrom disruption to maturity: the prognosis for the Global Biologics market in an era of transformative new technologies, payer pushback and biosimilars\n\t\t\t<\/a>\n\t<\/h3>\n\t

Sarah Rickwood has 20 years\u2019 experience as a consultant to the pharmaceutical industry, starting at Accenture\u2019s pharmaceutical strategy practice before joining QuintilesIMS Management Consulting. She has wide-ranging knowledge of international pharmaceutical industry issues, having worked with most of the world\u2019s leading pharmaceutical companies in the US, Europe, Japan, and leading emerging markets.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32484″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/shane-maloney\/shane_maloney_biotech_pharma_porto_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"","camera":"NIKON D3100","caption":"","created_timestamp":"1454006922","copyright":"","focal_length":"55","iso":"100","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Shane_Maloney_BioTech_Pharma_Porto_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Shane_Maloney_BioTech_Pharma_Porto_profile-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tShane Maloney\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Transaction Director at AstraZeneca<\/h5>\n

\n\t\t\t\n\tDeveloping partnerships and making deals\n\t\t\t<\/a>\n\t<\/h3>\n\t

Shane Maloney is a Transaction Director in AstraZeneca\u2019s business development group, based in Gothenburg, Sweden. He has worked in business development for AstraZeneca since 2001, originally in the UK and now in Sweden; and starting with technology platforms and early-discovery deals, before gradually moving to clinical-stage and on-market deals.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32399″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/steinar-madsen\/steinar_madsen_biotech_pharma_summit_norwegian_medicine_agency_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"1.8","credit":"","camera":"NIKON D300S","caption":"","created_timestamp":"1240011838","copyright":"","focal_length":"50","iso":"200","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSteinar Madsen\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Medical Director at Norwegian Medicines Agency<\/h5>\n

\n\t\t\t\n\tFrom biosimilar approval to biogenerics in clinical practice\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost-effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32496″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/unmesh-lal\/unmesh_frost_biotech_pharma_summit_profile\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Unmesh_frost_Biotech_Pharma_Summit_profile” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Unmesh_frost_Biotech_Pharma_Summit_profile-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tUnmesh Lal\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Program Manager, Life Sciences at Frost & Sullivan<\/h5>\n

\n\t\t\t\n\tData-driven Solutions Transforming the Global Biopharmaceuticals Manufacturing Industry\n\t\t\t<\/a>\n\t<\/h3>\n\t

His industry expertise lies among life sciences engagements across various therapeutic areas, leveraging relationships with key opinion leaders in sectors such as Global Pharmaceutical & Biologics Contract Outsourcing, API manufacturing in India & China, European Oncology & Diabetes market prognosis & Pharma sales force effectiveness.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32436″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/uwe-gudat\/uwe_gudat_fresenius_kabi_merck_biotech_pharma_summit_profile_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Uwe_Gudat_Fresenius_Kabi_Merck_BioTech_Pharma_Summit_Profile_1-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tUwe Gudat\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of Safety, Biosimilars at Fresenius Kabi SwissBioSim GmbH<\/h5>\n

\n\t\t\t\n\tWhat\u2019s in it for me: accounting for and reconciling multiple stakeholder perspectives in the adoption of biosimilars\n\t\t\t<\/a>\n\t<\/h3>\n\t

Uwe Gudat joined the pharmaceutical industry in 1995 with Eli Lilly and since then has held positions at Hesperion\/Actelion, Novartis and Merck Serono. In this time he has led global clinical development teams, served as global medical brand director, led clinical teams for in-licensing due-diligence and managed clinical-trial review, first in man transitions and product safety assessments. Currently he is Head of Safety of the Merck Serono Biosimilars Unit.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Our Speakers (A-Z) Ant\u00f3nio Pregueiro Vice President Life Sciences Europe at HighPoint Solutions Biosimilars: A market to grow Ant\u00f3nio Pregueiro, PhD has over 12 years of experience in the pharmaceutical and biotechnology industries combined with a strong research background prior to his business career. Following his graduate training, he spent 5 years working in consulting…<\/p>\n","protected":false},"author":1,"featured_media":32387,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-32386","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nBiosimilars & Biologics 2017 Speakers • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"The BioTech Pharma Summit \u2013 Biosimilars & Biologics 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosimilars & Biologics 2017 Speakers • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"The BioTech Pharma Summit \u2013 Biosimilars & Biologics 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T11:13:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/BioTech_Pharma_Summit_Biosimilars_Biologics_2017.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/\",\"name\":\"Biosimilars & Biologics 2017 Speakers • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/BioTech_Pharma_Summit_Biosimilars_Biologics_2017.png\",\"datePublished\":\"2020-07-21T10:15:21+00:00\",\"dateModified\":\"2021-03-18T11:13:27+00:00\",\"description\":\"The BioTech Pharma Summit \u2013 Biosimilars & Biologics 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/BioTech_Pharma_Summit_Biosimilars_Biologics_2017.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/BioTech_Pharma_Summit_Biosimilars_Biologics_2017.png\",\"width\":1920,\"height\":1152},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars & Biologics 2017 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biosimilars & Biologics 2017 Speakers • BioTech Pharma Summit","description":"The BioTech Pharma Summit \u2013 Biosimilars & Biologics 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Biosimilars & Biologics 2017 Speakers • BioTech Pharma Summit","og_description":"The BioTech Pharma Summit \u2013 Biosimilars & Biologics 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T11:13:27+00:00","og_image":[{"width":1920,"height":1152,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/BioTech_Pharma_Summit_Biosimilars_Biologics_2017.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/","name":"Biosimilars & Biologics 2017 Speakers • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/BioTech_Pharma_Summit_Biosimilars_Biologics_2017.png","datePublished":"2020-07-21T10:15:21+00:00","dateModified":"2021-03-18T11:13:27+00:00","description":"The BioTech Pharma Summit \u2013 Biosimilars & Biologics 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/BioTech_Pharma_Summit_Biosimilars_Biologics_2017.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/BioTech_Pharma_Summit_Biosimilars_Biologics_2017.png","width":1920,"height":1152},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Biosimilars & Biologics 2017 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=32386"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32386\/revisions"}],"predecessor-version":[{"id":35961,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32386\/revisions\/35961"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/32387"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=32386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}